Diclofenac epolamine medicated plaster in the treatment of minor soft tissue injuries: a multicenter randomized controlled trial

Li, Chunde; Frangione, Valeria; Rovati, Stefano; Zheng, Qingshan

doi:10.1185/03007995.2013.816669

Cited by 10 publications

(8 citation statements)

References 17 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Regarding safety we can compare the results with those presented in other studies in which it was observed that topical and placebo NSAIDs were well tolerated and there were no statistically significant differences between them [7,23]. Even though we did not determine the concentrations reached in plasma, indirectly we can assume that these were minimal since no systemic adverse effects related to Celecoxib were reported.…”

Section: Discussionmentioning

confidence: 78%

See 1 more Smart Citation

Celecoxib 2% Cream in Acute Soft Tissue Injuries: Randomized, Double-blind, Placebo-controlled Clinical Trial

Geannyne¹,

Amador²,

Silvia³

et al. 2017

Clin Res Foot Ankle

View full text Add to dashboard Cite

Objective: The aim of the study was to evaluate the efficacy of pain reduction and tolerability of topical administration of Celecoxib 2% cream compared to Celecoxib 1% cream and placebo cream in Mexican patients who had acute soft tissue injury in lower limbs. Methods:A randomized, double-blind, placebo control trial with 3 parallel groups was conducted. We include Mexicans patients older than 18 years with diagnosis of acute soft tissue injury in lower limbs. They were randomly assigned to Celecoxib 2% cream (CEL-2), Celecoxib 1% cream (CEL-1) or placebo cream (PLA). All treatments should be applied 3 times a day for a period of 7 days. Every day the pain was assessed with a Visual Analogue Scale (VAS). Secondary, we evaluate inflammation and adverse events.Results: A total of 95 patients were included. VAS on day 1 and 7 in group CEL-2 were 57.41 ± 10.39 mm and 4.34 ± 7.02 mm, in CEL-1 59.38 ± 9.37 mm and 10.41 ± 12.78 mm, and in PLA 55.61 ± 8.09 mm and 9.32 ± 9.93 mm. CEL-2 showed greater pain decrease compared to CEL-1 and PLA, p<0.05. CEL-1 group significantly decreased inflammation more than PLA, p<0.05. 15 adverse events were reported in 9 patients, none was severe. Conclusion:The results shown in the present study demonstrate that topical administration of Celecoxib cream 2%, TID for 7 days was effective in pain relief in patients with acute soft tissue injury.

show abstract

Section: Discussionmentioning

confidence: 78%

“…Because of the adverse gastrointestinal effects of NSAIDs, effective topical formulations have been successfully used in pain relief of muscle injuries such as sprains and bruises compared to placebo [6][7][8].…”

Section: Introductionmentioning

confidence: 99%

Celecoxib 2% Cream in Acute Soft Tissue Injuries: Randomized, Double-blind, Placebo-controlled Clinical Trial

Geannyne¹,

Amador²,

Silvia³

et al. 2017

Clin Res Foot Ankle

View full text Add to dashboard Cite

show abstract

“…Diclofenac is a nonsteroidal anti‐inflammatory drug (NSAID) that has been in clinical use for many years, particularly for the treatment of inflammatory and degenerative rheumatic diseases, and the pain resulting from minor soft tissue injuries . It is also effective in treating other painful non‐rheumatic and inflammatory conditions, such as dysmenorrhea and post‐operative pain .…”

mentioning

confidence: 99%

“…Diclofenac is a nonsteroidal anti-inflammatory drug (NSAID) that has been in clinical use for many years, particularly for the treatment of inflammatory and degenerative rheumatic diseases, and the pain resulting from minor soft tissue injuries. [1][2][3] It is also effective in treating other painful non-rheumatic and inflammatory conditions, such as dysmenorrhea and post-operative pain. 4,5 The mechanism of action for its anti-inflammatory, anti-nociceptive, and anti-pyretic effects is not completely understood but likely arises from inhibition of cyclooxygenase, an early component of the arachidonic acid cascade, resulting in reduced formation of prostaglandins, thromboxanes, and prostacyclin.…”

mentioning

confidence: 99%

Differential Pharmacokinetics of Diclofenac Potassium for Oral Solution vs Immediate‐Release Tablets From a Randomized Trial: Effect of Fed and Fasting Conditions

et al. 2014

View full text Add to dashboard Cite

Diclofenac potassium oral solution and tablet formulations produced statistically significantly different Cmax and tmax but similar AUC under fed and fasting conditions. Fed conditions produced significantly lower Cmax for both formulations and profoundly delayed tmax for the tablet, but had no effect on tmax for the solution formulation. These data provide insights into the importance of an earlier and greater exposure to diclofenac arising from the solution formulation than the tablet, which may account for the superiority in the onset and sustained pain reduction for the solution than the tablet formulation observed in the double-blind, efficacy/safety study in migraine patients conducted in Europe.

show abstract

“…• Medicated-patches The medicated-patches containing local anesthetic (lidocaine) [2][3][4] or antiinflammatory (NSAIDs) are used to manage patients with select pain condition (acute and chronic). A topical patch containing diclofenac epolamine, available in more than 40 countries worldwide, was approved for use in Europe since 1993 (2007 in USA), and the available postmarketing surveillance data offers good safety data [5][6][7]. The local treatment of soft-tissue rheumatism with flurbiprofen (40mg) patch versus oral therapy with diclofenac sodium provided both efficacy and good tolerability [8].…”

Section: Introductionmentioning

confidence: 99%

Topical patches as treatments for the management of patient musculoskeletal and neuropathic pain

Mirel¹,

Colobățiu²,

Mirel³

et al. 2017

BALNEO

View full text Add to dashboard Cite

The variety and multiple dimensions of pain (acute/chronic, mild/moderate/severe, nociceptive/neuropathic) requires different pharmacologic and non-pharmacologic treatments in certain patients. A lot of topical formulation, from various therapeutic classes have been proposed in order to decrease systemic exposure and to reduce the risks of adverse events. Topical as well as transdermal drug delivery systems are proposed as medicated plasters with: anesthetics (lidocaine), analgesic or nonsteroidal anti-inflamatory drugs (NSAIDs), alone or co-formulated. Capsaicin, salicylates, menthol and camphor represent the counterirritant class of topical analgesics used as patch active compounds. These compounds produce their analgesic effect by activating and desensitizing epidermal nociceptors. The most used topical treatment in order to decrease pain is the application of cold and heat patches-by acting directly on the affected tissue. In many cases there is a limited number of studies providing insufficient information to clinicians in order to evaluate the benefits of these products. This paper reviews the use and efficacy of available self-adhesing occlusive medicated plaster (pain patches) that might represent an alternative option for the management of patient pain, specially in the case of musculoskeletal and neuropathic disorders.

show abstract

Diclofenac epolamine medicated plaster in the treatment of minor soft tissue injuries: a multicenter randomized controlled trial

Cited by 10 publications

References 17 publications

Celecoxib 2% Cream in Acute Soft Tissue Injuries: Randomized, Double-blind, Placebo-controlled Clinical Trial

Celecoxib 2% Cream in Acute Soft Tissue Injuries: Randomized, Double-blind, Placebo-controlled Clinical Trial

Differential Pharmacokinetics of Diclofenac Potassium for Oral Solution vs Immediate‐Release Tablets From a Randomized Trial: Effect of Fed and Fasting Conditions

Topical patches as treatments for the management of patient musculoskeletal and neuropathic pain

Contact Info

Product

Resources

About